TY 2017 Form 990 Schedule J

(A) Name and Title		(B) Breakdown of W-2 and/or 1099-MISC compensation			(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation in column (B) reported as deferred on prior Form 990
(A) Name and Title		(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other reportable compensation	(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)
1PRESTON CAMPBELL MD PRESIDENT & CEO	(i) (ii)	369,858 ------------- 186,037	266,400 ------------- 131,212	169,507 ------------- 79,561	131,074 ------------- 51,107	25,026 ------------- 0	961,865 ------------- 447,917	132,835 ------------- 65,426
2JACK MAHLER MD CHIEF INVESTMENT OFFICER	(i) (ii)	542,149 ------------- 0	650,000 ------------- 0	4,903 ------------- 0	127,312 ------------- 0	25,026 ------------- 0	1,349,390 ------------- 0	0 ------------- 0
3MARC S GINSKY EXECUTIVE VP, COO & SECRETARY	(i) (ii)	467,890 ------------- 0	174,227 ------------- 0	21,094 ------------- 0	190,903 ------------- 0	35,110 ------------- 0	889,224 ------------- 0	68,247 ------------- 0
4VERA H TWIGG EXECUTIVE VP & CFO	(i) (ii)	328,670 ------------- 0	178,036 ------------- 0	18,000 ------------- 0	92,640 ------------- 0	35,110 ------------- 0	652,456 ------------- 0	41,058 ------------- 0
5ROBERT J BEALL PHD FORMER CEO/CURRENT CONSULTANT	(i) (ii)	269,500 ------------- 0	70,350 ------------- 34,650	43,244 ------------- 21,299	0 ------------- 0	0 ------------- 0	383,094 ------------- 55,949	28,879 ------------- 14,224
6C RICHARD MATTINGLY FORMER COO	(i) (ii)	0 ------------- 0	0 ------------- 0	197,010 ------------- 0	0 ------------- 0	0 ------------- 0	197,010 ------------- 0	72,855 ------------- 0
7DRUCY S BOROWITZ MD SENIOR VP, COMMUNITY AFFAIRS	(i) (ii)	375,062 ------------- 0	89,579 ------------- 0	5,725 ------------- 0	32,312 ------------- 0	0 ------------- 0	502,678 ------------- 0	0 ------------- 0
8TIMOTHY A WAIRE JR CHIEF INFORMATION OFFICER	(i) (ii)	275,487 ------------- 0	65,077 ------------- 0	959 ------------- 0	32,312 ------------- 0	32,778 ------------- 0	406,613 ------------- 0	0 ------------- 0
9GLEN GOLDMARK SENIOR VP OF HUMAN RESOURCES	(i) (ii)	276,817 ------------- 0	71,627 ------------- 0	6,741 ------------- 0	32,312 ------------- 0	22,626 ------------- 0	410,123 ------------- 0	0 ------------- 0
10ALBERT FARO MD SR DIRECTOR, CLINICAL AFFAIRS	(i) (ii)	296,937 ------------- 0	21,113 ------------- 0	1,540 ------------- 0	27,312 ------------- 0	34,424 ------------- 0	381,326 ------------- 0	0 ------------- 0
11MARYBETH MCMAHON PHD CHIEF OF STAFF	(i) (ii)	264,894 ------------- 0	64,710 ------------- 0	2,605 ------------- 0	32,312 ------------- 0	20,605 ------------- 0	385,126 ------------- 0	0 ------------- 0
12BRUCE MARSHALL MD SENIOR VP, CLINICAL AFFAIRS	(i) (ii)	335,833 ------------- 79,113	89,144 ------------- 21,000	5,381 ------------- 1,268	26,151 ------------- 6,161	185 ------------- 43	456,694 ------------- 107,585	0 ------------- 0
13WILLIAM SKACH MD SENIOR VP, RESEARCH AFFAIRS	(i) (ii)	58,183 ------------- 329,703	15,227 ------------- 86,284	951 ------------- 5,388	4,847 ------------- 27,465	5,266 ------------- 29,843	84,474 ------------- 478,683	0 ------------- 0

Schedule J (Form 990) 2017

Page 3

Part III

Supplemental Information

Provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4a, 4b, 4c, 5a, 5b, 6a, 6b, 7, and 8, and for Part II. Also complete this part for any additional information.

Return Reference	Explanation
PART I, LINE 4A SEVERANCE PAYMENTS:	A FORMER OFFICER LISTED ON THE FORM 990, PART VII, SECTION A RECEIVED PAYMENTS UNDER A SEVERANCE ARRANGEMENT, AS DESCRIBED IN FURTHER DETAIL IN SCHEDULE J, PART III, FOOTNOTE 9, BELOW.
PART I, LINE 4B - SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN:	CERTAIN PERSONS LISTED IN FORM 990, PART VII, SECTION A PARTICIPATE IN A NONQUALIFIED DEFERRED COMPENSATION PLAN, UNDER WHICH INTERESTS ARE FORFEITED BY THE PARTICIPANT IF THE PARTICIPANT VOLUNTARILY TERMINATES EMPLOYMENT PRIOR TO THE DESIGNATED VESTING DATE. FURTHER INFORMATION ABOUT THE NONQUALIFIED DEFERRED COMPENSATION PLAN IN WHICH THOSE PERSONS PARTICIPATE, INCLUDING THE AMOUNT OF ANY PAYMENT MADE BY THE PLAN DURING THE REPORTING YEAR, IS PROVIDED IN THE ADDITIONAL INFORMATION FOR SCHEDULE J, PART II, BELOW.
PART I, LINE 7	SEVERAL INDIVIDUALS LISTED IN FORM 990, PART VII, SECTION A, LINE 1A, PARTICIPATED IN THE FOUNDATION'S INCENTIVE COMPENSATION PLAN, FROM WHICH NON-FIXED PAYMENTS NOT DESCRIBED IN LINES 5 AND 6 WERE PAID. THE INCENTIVE COMPENSATION PLAN PAYS NON-FIXED PAYMENTS SUBJECT TO, AND BASED ON, THE ACHIEVEMENT OF ANNUAL PERFORMANCE OBJECTIVES ESTABLISHED IN ADVANCE BY THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES. IN ADDITION, THE INCENTIVE COMPENSATION PLAN PAYS NON-FIXED PAYMENTS THAT RELATE TO A THREE-YEAR PERFORMANCE PERIOD, SUBJECT TO, AND BASED ON, THE ACHIEVEMENT OF LONG-TERM PERFORMANCE OBJECTIVES ESTABLISHED IN ADVANCE BY THE COMPENSATION COMMITTEE OF THE BOARD. ANY FINANCIAL PERFORMANCE OBJECTIVES ESTABLISHED UNDER THE INCENTIVE COMPENSATION PLAN DO NOT INCLUDE PROGRAM-RELATED REVENUES SUCH AS ROYALTY STREAMS, LUMP-SUM PAYMENTS, AND SALES PROCEEDS FROM TRANSFER OF THE FOREGOING TO THIRD PARTIES RELATED TO THE DEVELOPMENT AND APPROVAL OF CF DRUGS.
PART II	CYSTIC FIBROSIS FOUNDATION. (A) NAME: P. CAMPBELL, M.D.; (B)(I) BASE COMPENSATION: BASE SALARY - $369,858; (B)(II) BONUS & INCENTIVE COMPENSATION: ANNUAL INCENTIVE PLAN BENEFIT (1) $128,875, LONG-TERM INCENTIVE PLAN PAYMENT, WHICH WAS PREVIOUSLY REPORTED (6) - $67,175, LONG-TERM INCENTIVE PLAN TREATMENT AWARD (10) $70,350; (B)(III) OTHER REPORTABLE COMPENSATION: TAXABLE GENERAL ORGANIZATION GROUP TERM LIFE INSURANCE PREMIUM - $7,524, AUTOMOBILE ALLOWANCE - $4,824, OTHER BENEFITS - $8,825, VESTED SERP ACCOUNT (8) - $148,334; (C) DEFERRED COMPENSATION: RETIREMENT BENEFIT (2) $27,312, LONG-TERM INCENTIVE PLAN BENEFIT (6) - $103,762; (D) NONTAXABLE BENEFITS: EMPLOYER CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $17,173, EMPLOYEE CONTRIBUTION TO FLEXIBLE SPENDING ACCOUNT BENEFIT - $2,600, EMPLOYEE CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $5,253; (F) COMPENSATION REPORTED IN PRIOR FORM 990 (3) - $132,835. CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. EIN 91-2059167. (A) NAME: P. CAMPBELL, M.D.; (B)(I) BASE COMPENSATION: BASE SALARY - $186,037; (B)(II) BONUS & INCENTIVE COMPENSATION: ANNUAL INCENTIVE PLAN BENEFIT (1) $63,476, LONG-TERM INCENTIVE PLAN PAYMENT, WHICH WAS PREVIOUSLY REPORTED (6) - $33,086, LONG-TERM INCENTIVE PLAN TREATMENT AWARD (10) $34,650; (B)(III) OTHER REPORTABLE COMPENSATION: AUTOMOBILE ALLOWANCE - $2,376, OTHER BENEFITS - $4,125, VESTED SERP ACCOUNT (8) - $73,060; (C) DEFERRED COMPENSATION: LONG-TERM INCENTIVE PLAN BENEFIT (6) - $51,107; (F) COMPENSATION REPORTED IN PRIOR FORM 990 (3) - $65,426. CYSTIC FIBROSIS FOUNDATION. (A) NAME: M. GINSKY.; (B)(I) BASE COMPENSATION: BASE SALARY - $467,890; (B)(II) BONUS & INCENTIVE COMPENSATION: ANNUAL INCENTIVE PLAN BENEFIT (1) $81,980, LONG-TERM INCENTIVE PLAN PAYMENT, WHICH WAS PREVIOUSLY REPORTED (6) - $68,247, LONG-TERM INCENTIVE PLAN TREATMENT AWARD (10) $24,000; (B)(III) OTHER REPORTABLE COMPENSATION: OTHER BENEFITS INCLUDING TAXABLE GENERAL ORGANIZATION GROUP TERM LIFE INSURANCE PREMIUM - $3,094, SECTION 457(B) PLAN (5) - $18,000; (C) DEFERRED COMPENSATION: RETIREMENT BENEFIT (2) $27,312, LONG-TERM INCENTIVE PLAN BENEFIT (6) - $136,717, SERP (4) - $26,874; (D) NONTAXABLE BENEFITS: EMPLOYER CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $24,855, EMPLOYEE CONTRIBUTION TO FLEXIBLE SPENDING ACCOUNT BENEFIT - $2,600, EMPLOYEE CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $7,655; (F) COMPENSATION REPORTED IN PRIOR FORM 990 (3) - $68,247. CYSTIC FIBROSIS FOUNDATION. (A) NAME: V. TWIGG; (B)(I) BASE COMPENSATION: BASE SALARY - $328,670; (B)(II) BONUS & INCENTIVE COMPENSATION: ANNUAL INCENTIVE PLAN BENEFIT (1) $84,478, LONG-TERM INCENTIVE PLAN PAYMENT, WHICH WAS PREVIOUSLY REPORTED (6) - $41,058, LONG-TERM INCENTIVE PLAN TREATMENT AWARD (10) $52,500; (B)(III) OTHER REPORTABLE COMPENSATION: SECTION 457(B) PLAN (5) - $18,000; (C) DEFERRED COMPENSATION: RETIREMENT BENEFIT (2) $27,312, LONG-TERM INCENTIVE PLAN BENEFIT (6) - $57,391, SERP (4) - $7,937; (D) NONTAXABLE BENEFITS: EMPLOYER CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $24,855, EMPLOYEE CONTRIBUTION TO FLEXIBLE SPENDING ACCOUNT BENEFIT - $2,600, EMPLOYEE CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $7,655; (F) COMPENSATION REPORTED IN PRIOR FORM 990 (3) - $41,058. CYSTIC FIBROSIS FOUNDATION. (A) NAME: J. MAHLER; (B)(I) BASE COMPENSATION: BASE SALARY - $542,149; (B)(II) BONUS & INCENTIVE COMPENSATION: ANNUAL INCENTIVE PLAN BENEFIT (1) $650,000; (B)(III) OTHER REPORTABLE COMPENSATION: OTHER BENEFITS INCLUDING TAXABLE GENERAL ORGANIZATION GROUP TERM LIFE INSURANCE PREMIUM - $4,903; (C) DEFERRED COMPENSATION: RETIREMENT BENEFIT (2) $27,312, SERP (4) - $100,000; (D) NONTAXABLE BENEFITS: EMPLOYER CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $17,174, EMPLOYEE CONTRIBUTION TO FLEXIBLE SPENDING ACCOUNT BENEFIT - $2,600, EMPLOYEE CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $5,252. CYSTIC FIBROSIS FOUNDATION. (A) NAME: R. BEALL, PH.D.; (B)(I) BASE COMPENSATION: EXECUTIVE ADVISORY CONSULTING SERVICES FEES - $269,500; (B)(II) BONUS & INCENTIVE COMPENSATION: LONG-TERM INCENTIVE PLAN TREATMENT AWARD (10) $70,350; (B)(III) OTHER REPORTABLE COMPENSATION: SECTION 457(B) PLAN DISTRIBUTION (7) - $43,244; (F) COMPENSATION REPORTED IN PRIOR FORM 990 (3) - $28,879. CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. EIN 91-2059167. (A) NAME: R. BEALL, PH.D.; (B)(II) BONUS & INCENTIVE COMPENSATION: LONG-TERM INCENTIVE PLAN TREATMENT AWARD (10) $34,650; (B)(III) OTHER REPORTABLE COMPENSATION: SECTION 457(B) PLAN DISTRIBUTION (7) - $21,299 (F) COMPENSATION REPORTED IN PRIOR FORM 990 (3) - $14,224. CYSTIC FIBROSIS FOUNDATION. (A) NAME: R. MATTINGLY; (B)(III) OTHER REPORTABLE COMPENSATION: SECTION 457(B) PLAN DISTRIBUTION (7) - $92,255; SEVERANCE PAY (9) - $104,755; (F) COMPENSATION REPORTED IN PRIOR FORM 990 (3) - $72,855. (1) THIS IS AN AWARD SUBJECT TO, AND BASED ON, ACHIEVEMENT OF ANNUAL PERFORMANCE STANDARDS ESTABLISHED IN ADVANCE BY THE COMPENSATION COMMITTEE OF THE BOARD. ANY FINANCIAL PERFORMANCE OBJECTIVES ESTABLISHED UNDER THE INCENTIVE COMPENSATION PLAN DO NOT INCLUDE PROGRAM-RELATED REVENUES SUCH AS ROYALTY STREAMS, LUMP-SUM PAYMENTS, AND SALES PROCEEDS FROM TRANSFER OF THE FOREGOING TO THIRD PARTIES RELATED TO THE DEVELOPMENT AND APPROVAL OF CF DRUGS. (2) THIS IS THE EMPLOYER CONTRIBUTION MADE UNDER THE CYSTIC FIBROSIS FOUNDATION 401(K) PLAN FOR THE 2017 PLAN YEAR. (3) THIS AMOUNT IS INCLUDED IN COLUMN B OF THIS FORM 990 AND HAS ALREADY BEEN PREVIOUSLY REPORTED AS COMPENSATION ON PRIOR YEARS' FORM 990S, AND THEREFORE (AS REQUIRED BY THE INSTRUCTIONS) IS DOUBLE-REPORTED. (4) A. THIS IS AN UNVESTED EMPLOYER CONTRIBUTION TO THE SERP. B. SERP INTERESTS ARE FORFEITED BY THE PARTICIPANT IF THE PARTICIPANT VOLUNTARILY TERMINATES EMPLOYMENT PRIOR TO ATTAINING THE VESTING DATE DESIGNATED BY CFF (WHICH IS EITHER A SPECIFIED AGE OR DATE, DEPENDING ON THE PARTICIPANT). C. SERP INTERESTS ARE HELD IN A TRUST SUBJECT TO THE CLAIMS OF CFF'S BANKRUPTCY CREDITORS. IN THE EVENT OF A CFF BANKRUPTCY, PARTICIPANTS WOULD BECOME GENERAL UNSECURED CREDITORS OF CFF. D. THE SERP IS A NONQUALIFIED DEFERRED COMPENSATION PLAN. THIS MEANS THAT PARTICIPANTS DO NOT RECEIVE THE TAX BENEFITS AVAILABLE TO PARTICIPANTS IN TAX QUALIFIED RETIREMENT PLANS. FOR EXAMPLE, UNDER CURRENT LAW, INTERESTS UNDER SERPS ARE REPORTABLE AS TAXABLE COMPENSATION WHEN THEY BECOME VESTED, EVEN IF THOSE AMOUNTS ARE NOT YET PAYABLE TO THE PARTICIPANT (AND EVEN IF THOSE AMOUNTS ARE NEVER PAID TO THE PARTICIPANT). E. THE SERP'S DESIGN WAS REVIEWED AND OPINED UPON AS REASONABLE BY AN INDEPENDENT COMPENSATION CONSULTANT. SERP CONTRIBUTION AMOUNTS WERE DETERMINED BY AN INDEPENDENT ACTUARY. F. CFF RETAINS THE RIGHT TO AMEND OR TERMINATE THE SERP AT ANY TIME. (5) A. THIS IS A VESTED CONTRIBUTION TO THE 457(B) PLAN FOR THE REPORTING PERIOD. B. IN THE EVENT OF A CFF BANKRUPTCY, PARTICIPANTS ARE GENERAL UNSECURED CREDITORS OF CFF. C. DISTRIBUTIONS FROM THE 457(B) PLAN MAY NOT BE ROLLED-OVER TO AN IRA OR QUALIFIED PLAN (BUT MAY ONLY BE ROLLED-OVER TO ANOTHER 457(B) PLAN). D. THE 457(B) PLAN'S DESIGN WAS REVIEWED AND OPINED UPON AS REASONABLE BY AN INDEPENDENT COMPENSATION CONSULTANT. AN INDEPENDENT ACTUARY DEVELOPED THE CONTRIBUTION FORMULA PURSUANT TO WHICH 457(B) CONTRIBUTION AMOUNTS ARE DETERMINED. CONTRIBUTIONS TO THE 457(B) PLAN ARE SUBJECT TO ANNUAL IRS LIMITS ($18,000 FOR 2017). E. CFF RETAINS THE RIGHT TO AMEND OR TERMINATE THE 457(B) PLAN AT ANY TIME. (6) THIS PLAN PROVIDES FOR AWARDS THAT RELATE TO A THREE-YEAR PERFORMANCE PERIOD, SUBJECT TO, AND BASED ON, ACHIEVEMENT OF PERFORMANCE OBJECTIVES ESTABLISHED IN ADVANCE BY THE COMPENSATION COMMITTEE OF THE BOARD. ANY FINANCIAL PERFORMANCE OBJECTIVES ESTABLISHED UNDER THE INCENTIVE COMPENSATION PLAN DO NOT INCLUDE PROGRAM-RELATED REVENUES SUCH AS ROYALTY STREAMS, LUMP-SUM PAYMENTS, AND SALES PROCEEDS FROM TRANSFER OF THE FOREGOING TO THIRD PARTIES RELATED TO THE DEVELOPMENT AND APPROVAL OF CF DRUGS. EACH YEAR, A NEW THREE-YEAR PERFORMANCE PERIOD BEGINS. AS REQUIRED BY THE FORM 990 INSTRUCTIONS, THE AMOUNTS REPORTED IN COLUMN (C) ON THIS FORM 990 REFLECT AN ESTIMATE OF THE PORTION OF EACH AWARD THAT THE EXECUTIVE ACCRUED UNDER THE PLAN FOR PERFORMANCE IN 2017 (I.E., WITH RESPECT TO THE 2015-2017, 2016-2018 AND THE 2017-2019 PERFORMANCE PERIODS), BUT THE AMOUNTS REPORTED IN COLUMN (C) HAVE NOT BEEN EARNED, AWARDED OR PAID UNDER THE PLAN. THE INDIVIDUAL MUST BE EMPLOYED ON 12/31/17, 12/31/18 AND 12/31/19 TO BE ELIGIBLE TO RECEIVE FULL PAYMENT OF THE AWARD FOR THE 2015-2017, 2016-2018 AND THE 2017-2019 PERFORMANCE PERIODS, RESPECTIVELY. THE AWARD RELATING TO THE 3-YEAR PERFORMANCE PERIOD ENDING 12/31/16 WAS PAID IN 2017, AND IS PROPERLY REPORTED AGAIN (AS COMPENSATION IN COLUMN (B)(II)) ON THIS FORM 990 (EVEN THOUGH AN ESTIMATE OF THE PORTION OF THIS AWARD THAT THE EXECUTIVE ACCRUED UNDER THE PLAN FOR PERFORMANCE IN
PART II, CONTINUED	2016, 2015 AND 2014 WAS REPORTED IN COLUMN (C) OF THE FORM 990 FOR EACH OF THOSE YEARS). (7) THIS PAYMENT IS A DISTRIBUTION FROM THE 457(B) PLAN DESCRIBED IN FOOTNOTE (5) ABOVE. AS REQUIRED BY THE FORM 990 INSTRUCTIONS, BECAUSE CONTRIBUTIONS TO THIS PLAN ARE FULLY VESTED WHEN MADE, CONTRIBUTIONS TO THIS PLAN WERE PREVIOUSLY REPORTED IN THE YEARS CONTRIBUTED, IN COLUMN B(III) AS "OTHER REPORTABLE COMPENSATION". THOSE PREVIOUSLY REPORTED AMOUNTS ARE REFLECTED IN COLUMN F OF THIS FORM 990. (8) THIS AMOUNT BECAME VESTED AND TAXABLE IN 2017 UNDER THE SERP DESCRIBED IN FOOTNOTE (4) ABOVE, UNDER WHICH DR. CAMPBELL RECEIVED CONTRIBUTIONS FROM 2016-2017. AS REQUIRED, A PORTION OF THE CONTRIBUTIONS TO THIS SERP THAT GENERATED THE AMOUNT REPORTED IN COLUMN B(III) OF THIS FORM 990 WERE REPORTED ON PRIOR YEARS' FORM 990S IN COLUMN (C). THOSE PREVIOUSLY REPORTED AMOUNTS ARE REFLECTED IN COLUMN F OF THIS FORM 990. (9) AS PART OF A SEVERANCE AGREEMENT, THE EXECUTIVE RECEIVED THIS AMOUNT, WHICH RELATES TO (1) A PORTION OF THE AMOUNT THAT WOULD HAVE BEEN PAID TO HIM UNDER THE ORGANIZATION'S LONG TERM INCENTIVE COMPENSATION PLAN HAD HE CONTINUED EMPLOYMENT WITH THE ORGANIZATION THROUGH 12/31/16 AND (2) THE LONG TERM INCENTIVE PLAN TREATMENT AWARD (DESCRIBED IN FOOTNOTE 10, BELOW) THAT WOULD HAVE BEEN PAID TO HIM HAD HE CONTINUED EMPLOYMENT WITH THE ORGANIZATION TROUGH 12/31/18. THE LONG TERM INCENTIVE COMPENSATION PLAN AMOUNT RELATED TO A PORTION OF THE THREE-YEAR PERFORMANCE PERIOD (I.E., THE PORTION OF THE 2014-2016 PERFORMANCE PERIOD DURING WHICH THE EXECUTIVE WAS EMPLOYED BY THE ORGANIZATION), AND WAS SUBJECT TO, AND BASED ON, ACHIEVEMENT OF PERFORMANCE OBJECTIVES ESTABLISHED IN ADVANCE BY THE COMPENSATION COMMITTEE OF THE BOARD. ANY FINANCIAL PERFORMANCE OBJECTIVES ESTABLISHED UNDER THE INCENTIVE COMPENSATION PLAN DO NOT INCLUDE PROGRAM-RELATED REVENUES SUCH AS ROYALTY STREAMS, LUMP-SUM PAYMENTS, AND SALES PROCEEDS FROM TRANSFER OF THE FOREGOING TO THIRD PARTIES RELATED TO THE DEVELOPMENT AND APPROVAL OF CF DRUGS. (NOTE THAT AN ESTIMATE OF THE PORTION OF THIS AWARD THAT THE EXECUTIVE ACCRUED UNDER THE PLAN FOR PERFORMANCE WAS REPORTED IN COLUMN (C) OF THE FORM 990 FOR THE APPLICABLE YEARS. THE PREVIOUSLY REPORTED AMOUNT IS REFLECTED IN COLUMN F OF THIS FORM 990.) THE SEVERANCE AMOUNT WAS REVIEWED AND OPINED UPON AS REASONABLE BY AN INDEPENDENT COMPENSATION CONSULTANT AND APPROVED BY THE ORGANIZATION'S COMPENSATION COMMITTEE IN ACCORDANCE WITH THE IRS'S INTERMEDIATE SANCTIONS RULES. (10) THIS IS AN AWARD UNDER A PLAN THAT PAYS A SPECIFIED DOLLAR AMOUNT ONLY IF AND WHEN THE FDA APPROVES CERTAIN PRE-SPECIFIED TYPES OF THERAPIES. IN THE EVENT THE EMPLOYEE TERMINATES EMPLOYMENT PRIOR TO FDA APPROVAL OF THE SPECIFIED THERAPY TYPE AND PAYMENT OF THE AWARD, THE EMPLOYEE WILL FORFEIT HIS OR HER RIGHT TO RECEIVE PAYMENT, UNLESS THE EMPLOYEE IS AN OFFICER AND HIS/HER TERMINATION IS DUE TO RETIREMENT OR DISABILITY. THE PLAN TERMINATES ON DECEMBER 31, 2018.

Schedule J (Form 990) 2017

Additional Data

Software ID:
Software Version: